Avidia Acquisition Completes
Thousand Oaks-based Amgen has completed its acquisition of Mountain View-based Avidia, the firm said Tuesday afternoon. The previously announced acquisition was worth $290M. Avidia's lead product candidate is an inhibitor of interleukin 6, targeted at the treatment of inflammation and autoimmune diseases.
posted on Wednesday, October 25, 2006
Related stories:
> Avidia Acquired by Amgen
> Intoto Acquisition Completes
> Covad Communications Acquisition Completes
> Beceem Acquisition Completes
> AOL Completes $850M Bebo Buy
silicontap.com Home